Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer

Wu, YL; Zhang, L; Kim, DW; Liu, XQ; Lee, DH; Yang, JCH; Ahn, MJ; Vansteenkiste, JF; Su, WC; Felip, E; Chia, V; Glaser, S; Pultar, P; Zhao, S; Peng, B; Akimov, M; Tan, DSW

Wu, YL (reprint author), Guangdong Gen Hosp, Guangdong Lung Canc Inst, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China.; Wu, YL (reprint author), Guangdong Acad Med Sci, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China.

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (31): 3101

Abstract

PurposeMesenchymal-epithelial transition factor (MET) dysregulation occurs in up to 26% of non-small-cell lung cancers (NSCLCs) after epidermal growth......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索